Roberta Cristina Cintra Taveira

Mrs. Roberta Cristina Cintra Taveira

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OAOlga Laura Sena Almeida
Olga Laura Sena Almeida
EFEduardo Ferriolli
Eduardo Ferriolli
RTRoberta Cristina Cintra Taveira
Roberta Cristina Cintra Taveira
MRMeire Gallo Rosenburg
Meire Gallo Rosenburg
DCDaniela Dalpubel Campanari
Daniela Dalpubel Campanari
NLNereida K. C. Lima
Nereida K. C. Lima
This study compared mirtazapine with megestrol in the management of cancer-related anorexia–cachexia syndrome in patients with advanced cancer. A randomized, double-blind, controlled clinical trial involving patients with advanced cancer and anorexia–cachexia syndrome was performed. Participants received mirtazapine 30 mg/day or megestrol 320 mg/day for eight weeks. The primary endpoint was the effect of mirtazapine on weight gain and the secondary endpoints were its effect on appetite, muscle strength, physical performance, body composition, adverse events, and medication adherence. Linear regression model with mixed effects was applied and a significance level of 5% was adopted. Fifty-two patients were randomized. Mean age was 65.8 ± 8.4 years. There was weight gain in 52% of the participants in the megestrol group and in 38% in the mirtazapine group after four weeks (p = 0.040). Appetite improved in 92% of the participants in the megestrol group and in 56% in the mirtazapine group after eight weeks (p = 0.007). In the sub-analysis by sex, women showed improvement in appetite (p < 0.001) and weight gain (p < 0.005) in the mirtazapine group, which was not observed in men. Mirtazapine appears to be inferior to megestrol in weight and appetite improvement. However, there may be a difference in the therapeutic response between sexes.